Tharimmune (THAR) News Today $2.07 -0.03 (-1.43%) (As of 12/20/2024 05:30 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Rodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy RecommendationDecember 7, 2024 | msn.comTharimmune presents clinical data on TH104 for chronic pruritusNovember 19, 2024 | markets.businessinsider.comWhat's Going On With Tharimmune Shares Monday?November 18, 2024 | benzinga.comTharimmune, Inc. (NASDAQ:THAR) COO Purchases $10,100.00 in StockNovember 14, 2024 | insidertrades.comTharimmune granted patent for delivery of molecularly targeted therapeuticsNovember 13, 2024 | markets.businessinsider.comTharimmune Inc.: Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted TherapeuticsNovember 13, 2024 | finanznachrichten.deTharimmune receives regulatory feedback from EMA for TH104 programOctober 31, 2024 | markets.businessinsider.comWhat's Going On With Tharimmune Shares Wednesday?October 31, 2024 | msn.comTharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific MeetingOctober 28, 2024 | markets.businessinsider.comTharimmune (NASDAQ:THAR) Stock Quotes, Forecast and News SummaryOctober 1, 2024 | benzinga.comTHAR Stock Earnings: Tharimmune Reported Results for Q2 2024August 12, 2024 | investorplace.comTharimmune, Inc.: Tharimmune to Present at 2024 BIO International ConventionMay 29, 2024 | finanznachrichten.deTharimmune to Present at 2024 BIO International ConventionMay 29, 2024 | finance.yahoo.comShort Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 83.2%Tharimmune, Inc. (NASDAQ:THAR - Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 20,000 shares, a decline of 83.2% from the April 30th total of 119,000 shares. Based on an average daily trading volume, of 299,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the company's shares are sold short.May 28, 2024 | marketbeat.comWhy Is Tharimmune (THAR) Stock Moving Today?May 24, 2024 | investorplace.comWhy Tharimmune (THAR) Shares Are MovingMay 22, 2024 | msn.comTharimmune, Inc.: Tharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | finanznachrichten.deTharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | finance.yahoo.comTHAR Stock Earnings: Tharimmune Reported Results for Q4 2023May 9, 2024 | investorplace.comStonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus ManagementMay 2, 2024 | finance.yahoo.comTharimmune, Inc. (THAR)April 24, 2024 | finance.yahoo.comTharimmune Inc THARApril 18, 2024 | morningstar.comTharimmune forms advisory board to guide drug developmentApril 16, 2024 | investing.comTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialFebruary 21, 2024 | msn.comTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver DiseaseFebruary 20, 2024 | msn.comTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finanznachrichten.deTharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finance.yahoo.comTharimmune’s Active Common Stock Shares UpdateFebruary 9, 2024 | msn.comTharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary CholangitisFebruary 5, 2024 | finance.yahoo.comTharimmune, Inc.: Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business UpdateJanuary 29, 2024 | finanznachrichten.deTharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease PatientsDecember 11, 2023 | finance.yahoo.comTharimmune, Inc. Announces Closing of $11 Million Public OfferingNovember 30, 2023 | finance.yahoo.comWhy Tharimmune Stock (THAR) Is Down 70% TodayNovember 30, 2023 | msn.comWhy Is Liver Disease Focused Tharimmune Stock Trading Higher Today?November 29, 2023 | msn.comTharimmune Shares Hit 52-Week Low After Public Offering PricesNovember 29, 2023 | marketwatch.comTharimmune announces pricing of $10 million public offeringNovember 29, 2023 | msn.comCrude Oil Surges 2%; Tharimmune Shares PlummetNovember 29, 2023 | markets.businessinsider.comTharimmune, Inc. Announces Pricing of $10 Million Public OfferingNovember 29, 2023 | finance.yahoo.comWhy Is Tharimmune (THAR) Stock Down 70% Today?November 28, 2023 | investorplace.comTrading was temporarily halted for "THAR" at 07:11 PM with a stated reason of "News pending."November 21, 2023 | marketbeat.comWhy Is Tharimmune (THAR) Stock Up 113% Today?November 7, 2023 | investorplace.com Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private. Click here to see Dan's full warning to the public. THAR Media Mentions By Week THAR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THAR News Sentiment▼0.500.60▲Average Medical News Sentiment THAR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THAR Articles This Week▼10▲THAR Articles Average Week Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aspira Women's Health News Today ImmunoPrecise Antibodies News Today Imunon News Today CervoMed News Today Relmada Therapeutics News Today Talphera News Today Kazia Therapeutics News Today Turnstone Biologics News Today Sensei Biotherapeutics News Today Jaguar Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THAR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THAR Stock Alerts